Clinical data | |
---|---|
Trade names | Precedex, Dexdor, Igalmi, others |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous, transmucosal, intranasal, sublingual |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 94% (mostly albumin)[3] |
Metabolism | Near complete hepatic metabolism to inactive metabolites |
Elimination half-life | 2–4 hours[6] |
Excretion | Urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.119.391 |
Chemical and physical data | |
Formula | C13H16N2 |
Molar mass | 200.285 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Dexmedetomidine, sold under the trade name Precedex among others, is a drug used in humans for sedation.[3] Veterinarians use dexmedetomidine for similar purposes in treating cats, dogs, and horses.[7][8] It is also used in humans to treat acute agitation associated with schizophrenia or bipolar I or II disorder.[4]
Similar to clonidine, it is a sympatholytic drug that acts as an agonist of α2-adrenergic receptors in certain parts of the brain.[9] It was developed by Orion Pharma.
Weerink_2017
was invoked but never defined (see the help page).Cormack2005
was invoked but never defined (see the help page).